REG - Arix Bioscience Plc - Director/PDMR Shareholding

Arix BioscienceAnnouncement

31/05/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230531:nRSe1896Ba&default-theme=true

RNS Number : 1896B  Arix Bioscience Plc  31 May 2023

Arix Bioscience plc

(the "Company")

PDMR notification & Director Shareholding

The Company today announces it has granted an executive award of nil cost
options (the "Award") under the Arix Bioscience plc Executive Incentive Plan
(the "Plan") to CEO Robert Lyne, which are subject to performance conditions
over a three-year period from 1 January 2023 to 31 December 2025 (the
"Performance Period"). The Award takes the form of an option to acquire up to
671,800 ordinary shares of £0.00001 each in the Company. Vested Shares are
subject to a further two-year holding period, as set out in the Plan. The
performance conditions attached to the Award are set out in the Director's
Remuneration Report on page 55 of Company's Annual Report & Accounts 2022.

 

 1     Details of the person discharging managerial responsibilities / person closely

     associated

 a)    Name                                                         Robert Lyne

 2     Reason for the notification

 a)    Position/status                                              Chief Executive Officer

 b)    Initial notification /Amendment                              Initial Notification

 3     Details of the issuer, emission allowance market participant, auction

     platform, auctioneer or auction monitor

 a)    Name                                                         Arix Bioscience plc

 b)    LEI                                                          213800OVT3AHQCXNIX43

 4     Details of the transaction(s): section to be repeated for (i) each type of

     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument  Arix Bioscience plc Ordinary shares of 0.001 pence each

       Identification code                                          GB00BD045071
 b)    Nature of the transaction                                    Award of nil-cost options under the Arix Bioscience plc Executive Incentive

                                                            Plan ("EIP")

  c)   Price(s) and volume(s)                                                            Price(s)             Volume(s)
                                                                                         Nil                  671,800

 d)    Aggregated information

       - Aggregated volume                                          N/A (Single Transaction)
       - Price                                                      N/A (Single Transaction)
 e)    Date of the transaction                                      30 May 2023

 f)    Place of the transaction                                     Outside a trading venue

For further information please contact:

Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBFLFXXELEBBB